Genentech Partners In Pain With Xenon
This article was originally published in The Pink Sheet Daily
Executive Summary
As part of its burgeoning efforts in neuroscience, Genentech will discover and develop compounds and companion diagnostics for the treatment of pain, not an area the company historically has played in.
You may also be interested in...
Xenon Progresses Antisense Anemia Drug In Pact With Isis
Private drug developer Xenon will move forward development of the novel anemia drug XEN701 for patients with chronic kidney disease and pay $2 million to partner Isis.
Xenon Feels No Pain After $41M Upfront From Teva
Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.
Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit
Pfizer plans to buy its pain partner in a deal valued at $56 million, including the 11% of shares the big pharma already owns in Icagen.